|
Title
|
|
|
|
Added diagnostic value of CSF biomarkers in differential dementia diagnosis
|
|
|
Author
|
|
|
|
|
|
|
Abstract
|
|
|
|
| This study aimed to investigate whether cerebrospinal fluid (CSF) biomarkers could have helped the clinician in differential dementia diagnosis in case of clinically ambiguous diagnoses, as compared to autopsy-confirmed dementia diagnosis as gold standard. Twenty-two patients of our autopsy-confirmed dementia population totalling 157 patients had an ambiguous clinical diagnosis at CSF sampling and were included in statistical analysis. CSF levels of â-amyloid peptide (Aâ1-42), total tau protein (T-tau) and tau phosphorylated at threonine 181 (P-tau181P) were determined. A biomarker-based model was applied to discriminate between AD and NON-AD dementias. AD and NON-AD patients showed no significant differences in Aâ1-42 and T-tau concentrations, whereas P-tau181P concentrations were significantly higher in AD compared to NON-AD patients. The biomarker-based diagnostic model correctly classified 18 of 22 (82%) patients with clinically ambiguous diagnoses. Using a biomarker-based model in patients with clinically ambiguous diagnoses, a correct diagnosis would have been established in the majority of autopsy-confirmed AD and NON-AD cases, indicating that biomarkers have an added diagnostic value in cases with ambiguous clinical diagnoses. |
|
|
|
Language
|
|
|
|
English
|
|
|
Source (journal)
|
|
|
|
Neurobiology of aging. - Fayetteville, N.Y.
|
|
|
Publication
|
|
|
|
Fayetteville, N.Y.
:
2010
|
|
|
ISSN
|
|
|
|
0197-4580
|
|
|
DOI
|
|
|
|
10.1016/J.NEUROBIOLAGING.2008.10.017
|
|
|
Volume/pages
|
|
|
|
31
:11
(2010)
, p. 1867-1876
|
|
|
ISI
|
|
|
|
000282907800004
|
|
|
Full text (Publisher's DOI)
|
|
|
|
|
|